Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

• ClinicalTrials.gov Identifier: NCT04699188
• Recruitment Status: Recruiting
• First Posted: January 7, 2021
• Last Update Posted: May 6, 2022
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Tracking Information

• First Submitted Date: January 5, 2021
• First Posted Date: January 7, 2021
• Last Update Posted Date: May 6, 2022
• Actual Study Start Date: February 24, 2021
• Estimated Primary Completion Date: August 21, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 17, 2022)

• Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment [ Time Frame: 21 days ]
  A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment
• Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 24 months ]
  All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).
• Dose Escalation: Frequency of dose interruptions and reductions, by treatment [ Time Frame: 24 months ]
  Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.
• Dose Escalation: Dose intensity by treatment [ Time Frame: 24 months ]
• Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment [ Time Frame: 24 months ]
  Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI).

Original Primary Outcome Measures (submitted: January 5, 2021)

• Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment [ Time Frame: 18 months ]
• Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 24 months ]
• Dose Escalation: Frequency of dose interruptions and reductions, by treatment [ Time Frame: 24 months ]
• Dose Escalation: Dose intensity by treatment [ Time Frame: 24 months ]
• Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment [ Time Frame: 24 months ]

Current Secondary Outcome Measures (submitted: January 17, 2022)

• Dose Escalation and Expansion: ORR per RECIST v1.1 [ Time Frame: 24 months ]
  Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI)
• Dose Escalation and Expansion: Best Overall Response (BOR) per RECIST v1.1 [ Time Frame: 24 months ]
  BOR is defined as the best overall confirmed response recorded from the start of the treatment until disease progression/recurrence.
• Dose Escalation and Expansion: Progression-free survival (PFS) per RECIST v1.1, Overall Survival (OS) [ Time Frame: 24 months ]
  Per RECIST 1.1, PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death. If patient has not had an event, PFS will be censored at the date of last adequate tumor assessment. PFS will be summarized using the Kaplan-Meier method, along with 95% CI
• Dose Escalation and Expansion: Duration of Response (DOR) per RECIST v1.1 [ Time Frame: 24 months ]
  Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause. Estimates will use Kaplan-Meier method, and median DOR and corresponding 95% CI will be presented.
• Dose Escalation and Expansion: Disease Control Rate (DCR) per RECIST v1.1 [ Time Frame: 24 months ]
  The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease. It will be summarized along with the corresponding 95% exact CI
• Dose Escalation and Expansion: Plasma or serum concentration vs time profiles (AUC) by treatment [ Time Frame: Up to 24 months ]
  AUC is defined as area under the plasma or serum concentration versus time curve after a dose of JDQ443, TNO155 and tislelizumab
• Dose Escalation and Expansion: Plasma concentration (Cmax) by treatment [ Time Frame: Up to 24 months ]
  Cmax is defined as the maximum observed plasma or serum drug concentration after single dose administration.
• Dose Escalation and Expansion: Time to achieve Cmax (Tmax) by treatment [ Time Frame: Up to 24 months ]
  Tmax is defined as the time to reach maximum plasma or serum drug concentration after single dose administration.
• Dose Escalation and Expansion: Antidrug antibody (ADA) incidence by treatment [ Time Frame: Up to 24 months ]
  To evaluate the immunogenicity of tislelizumab when dosed in combination with JDQ443 and/or TNO155 - only applicable to Arms C and D
• Dose Expansion: Dose intensity by treatment [ Time Frame: 24 months ]
• Dose Expansion: Frequency of dose interruptions and reductions, by treatment [ Time Frame: 24 months ]
  Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.
• Dose Expansion: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment [ Time Frame: 21 days ]
  A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment
• Dose Expansion: Incidence and severity of AEs and SAEs by treatment [ Time Frame: 24 months ]

Original Secondary Outcome Measures (submitted: January 5, 2021)

• Dose Escalation and Expansion: ORR per RECIST v1.1 [ Time Frame: 24 months ]
• Dose Escalation and Expansion: Best Overall Response (BOR) per RECIST v1.1 [ Time Frame: 24 months ]
• Dose Escalation and Expansion: Progression-free survival (PFS) per RECIST v1.1, Overall Survival (OS) [ Time Frame: 24 months ]
• Dose Escalation and Expansion: Duration of Response (DOR) per RECIST v1.1 [ Time Frame: 24 months ]
• Dose Escalation and Expansion: Disease Control Rate (DCR) per RECIST v1.1 [ Time Frame: 24 months ]
• Dose Escalation and Expansion: Plasma or serum concentration vs time profiles (AUC) by treatment [ Time Frame: 18 months ]
• Dose Escalation and Expansion: Plasma concentration (Cmax) by treatment [ Time Frame: 18 months ]
• Dose Escalation and Expansion: Time to achieve Cmax (Tmax) by treatment [ Time Frame: 18 months ]
• Dose Escalation and Expansion: Antidrug antibody (ADA) incidence by treatment [ Time Frame: 24 months ]
• Dose Expansion: Frequency of dose interruptions and reductions, by treatment [ Time Frame: 24 months ]
• Dose Expansion: Dose intensity by treatment [ Time Frame: 24 months ]
• Dose Expansion: Incidence and severity of AEs and SAEs by treatment [ Time Frame: 24 months ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• Official Title: A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
• Brief Summary: This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• KRAS G12C Mutant Solid Tumors
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Colorectal
• Cancer of Lung
• Cancer of the Lung
• Lung Cancer
• Neoplasms, Lung
• Neoplasms, Pulmonary
• Pulmonary Cancer
• Pulmonary Neoplasms

Intervention

• Drug: JDQ443
  KRAS G12C inhibitor
• Drug: TNO155
  SHP2 inhibitor
• Biological: tislelizumab
  Anti PD1 antibody

Study Arms

• Experimental: Arm A
  JDQ443
  Intervention: Drug: JDQ443
• Experimental: Arm B
  JDQ443 in combination with TNO155
  Interventions:

  • Drug: JDQ443
  • Drug: TNO155
• Experimental: Arm C
  JDQ443 in combination with tislelizumab
  Interventions:

  • Drug: JDQ443
  • Biological: tislelizumab
• Experimental: Arm D
  JDQ443 in combination with TNO155 and tislelizumab
  Interventions:

  • Drug: JDQ443
  • Drug: TNO155
  • Biological: tislelizumab

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: January 17, 2022): 375
• Original Estimated Enrollment (submitted: January 5, 2021): 345
• Estimated Study Completion Date: August 21, 2024
• Estimated Primary Completion Date: August 21, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies
• ECOG Performance Status of 0 or 1
• At least one measurable lesion as defined by RECIST 1.1
• Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations

Exclusion Criteria:

• Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
• Active brain metastases
• Clinically significant cardiac disease or risk factors at screening
• A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Novartis Pharmaceuticals; 1-888-669-6682; novartis.email@novartis.com

Contact: Novartis Pharmaceuticals; +41613241111

• Listed Location Countries: Australia, Belgium, Canada, China, Denmark, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, United States

Administrative Information

• NCT Number: NCT04699188
• Other Study ID Numbers: CJDQ443A12101; 2020-004129-22 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Novartis ( Novartis Pharmaceuticals )
• Original Responsible Party: Same as current
• Current Study Sponsor: Novartis Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Novartis
• Verification Date: May 2022